Collegium Pharmaceutical (COLL) investor relations material

Strategic vision and business overview

• Focused on building a diversified biopharmaceutical company targeting CNS conditions and pain management, with six marketed products and a strong commitment to patient needs.

• Recent diversification into ADHD with JORNAY PM and AZSTARYS, both protected by patents until 2032 and 2037, respectively.

• Pain management remains a foundational business, with BELBUCA and Xtampza as core products and ongoing revenue despite initial generic competition for NUCYNTA.

• Significant revenue and cash generation, with projected 2026 revenues of $840 million and adjusted EBITDA of $460 million.

• Strategic priorities include accelerating ADHD growth, maximizing pain business durability, and disciplined capital allocation.

Financial performance and growth drivers

• 2026 revenue expected to grow 8% year-over-year, driven by ADHD portfolio, especially JORNAY PM (projected >30% growth) and initial AZSTARYS sales.

• Recent quarter saw 41% growth in JORNAY PM revenues, total pain revenue of $141 million, and 6% overall revenue growth.

• AZSTARYS acquisition expected to contribute $65–$75 million in partial-year revenue, with greater impact anticipated from 2027 onward.

• Adjusted EBITDA expected to remain flat in 2026 due to increased ADHD investment and NUCYNTA revenue declines.

• $50 million accelerated share repurchase program announced in August as part of capital allocation strategy.

ADHD and pain portfolio highlights

• JORNAY PM offers unique once-daily evening dosing, leading to high differentiation and strong prescriber adoption; 70% of surveyed HCPs plan to increase prescribing.

• JORNAY PM scripts up 13% year-over-year, with prescriber base growing 18% and branded methylphenidate market share rising to 29%.

• AZSTARYS is the first ADHD treatment combining fast and long-acting medicines in one capsule, targeting patients needing rapid onset and all-day efficacy.

• BELBUCA and Xtampza remain top-rated in their categories, with combined revenues expected to be flat as lower volumes are offset by improved profitability.

• BELBUCA exclusivity likely until 2032, as Teva has not pursued generic launch; Xtampza exclusivity projected until 2033.